Ipratropium
As of the edition of 20 October 2026, Ipratropium is a small molecule: marketed, first approved in 1986 (US); acts on CHRM3; no US protection is listed.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2003
- Kind
- Small molecule
- Brand name
- Atrovent
- First approved
- 29 December 1986 (US)
- Approvals on record
- 11 in 3 regions
- Holder of the most recent approval
- Boehringer Ingelheim; 2 holders in all
- Registered trials
- 61, 4 stopped early
- Disease areas
- Lungs and airways; Immune system; Infections; Mouth and teeth; Nervous system; Cancer
US protection
No US protection is listed.
The FDA registers list no drug-substance patent or exclusivity that counts for this drug.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| CHRM3 | Muscarinic acetylcholine receptor M3 | P20309 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 19 | 18 | 0 | 0 |
| Phase 1 | 6 | 6 | 0 | 0 |
| Phase 2 | 11 | 9 | 1 | 0 |
| Phase 3 | 11 | 9 | 0 | 2 |
| Phase 4 | 14 | 11 | 0 | 2 |
| All trials | 61 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Boehringer Ingelheim | Originator and Lead sponsor of trials | 1986 to now |